P - Contraindicated in pregnancy
L - Caution when used during lactation
FI - Food *
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
Single and multiple doses of 10 mg or more of Benazepril hydrochloride cause inhibition of plasma ACE activity by at least 80% to 90% for at least 24 hours after dosing. Pressor responses to exogenous angiotensin I were inhibited by 60% to 90% (up to 4 hours post-dose) at the 10 mg dose.
Benazepril and its metabolite benazeprilat inhibit ACE that catalyzes the conversion of angiotensin I to angiotensin II, thus leading to reduced aldosterone secretion by the adrenal cortex and decreased vasopressor activity.
Absorption 37% of dose is absorbed from the GI tract (oral); peak plasma concentrations after 1-2 hr (fasting state), 2-4 hr (nonfasting state).
Distribution Enters breast milk. Protein-binding: 95%.
Metabolism Hepatic (almost complete); converted to benazeprilat (active metabolite).
Excretion Mainly via urine; via bile (11-12% of dose); 10-11 hr (elimination half-life), may be slowed in renal impairment.
Information Not Available
Benazepril and its metabolite benazeprilat inhibit ACE that catalyzes the conversion of angiotensin I to angiotensin II, thus leading to reduced aldosterone secretion by the adrenal cortex and decreased vasopressor activity. Absorption: 37% of dose is absorbed from the GI tract (oral); peak plasma concentrations after 1-2 hr (fasting state), 2-4 hr (nonfasting state). Distribution: Enters breast milk. Protein-binding: 95%. Metabolism: Hepatic (almost complete); converted to benazeprilat (active metabolite). Excretion: Mainly via urine; via bile (11-12% of dose); 10-11 hr (elimination half-life), may be slowed in renal impairment.
Information Not Available
Valvular stenosis, before, during or immediately after anaesthesia, unilateral renal artery stenosis, preexisting renal insufficiency. Withdraw diuretics 2-3 days before benazepril treatment. SC epinephrine (1:1000) to be readily available in the event of angioedema. vol or salt-depleted states; collagen vascular disease; concomitant potassium supplements or potassium-sparing drugs; severe renal impairment (CrCl <30 ml/min). Lactation. Immunosuppressive therapy.
Thiazides and other diuretics may cause excessive fall in BP when used with benazepril. Increased risk of lithium toxicity when used concurrently. Potentially Fatal: Concomitant potassium-sparing diuretics or potassium supplements can increase the risk of hyperkalaemia.
Food interactions Rate of absorption delayed but the extent is not affected.
Oral Hypertension Adult: Initially, 10 mg once daily. Maintenance: 20-40 mg daily as a single or in 2 divided doses. Max dose: 80 mg/day. Child: ≥6 yr: 0.2 mg/kg/day. Max Dosage: 40 mg/day. Renal impairment: Avoid usage in children with CrCl <30 ml/min. CrCl (ml/min): <30 Dosage Recommendation: Initial dose: 5 mg daily. Max maintenance dose: 40 mg daily.
May be taken with or without food
Contraindicated in pregnancy. Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. In 2nd & 3rd trimesters: Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Caution when used during lactation
Information Not Available
Information Not Available
Hypersensitivity. History of bilateral renal artery stenosis, angioedema; pregnancy.
Information Not Available
Information Not Available
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.